HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA Claims Board Members, Former CFO 'Colluded' To Discredit, Dismiss Fabricant

This article was originally published in The Tan Sheet

Executive Summary

The complaint filed in federal court in Washington alleges a "long-planned surprise attack" as part of an attempt by representatives of the retail sector on the NPA board and by former chief financial officer Brent Weickert to discredit the trade group's executive director and CEO, Daniel Fabricant.

You may also be interested in...



NPA Agrees To Drop Complaint Of 'Shadow Board' Plot To Oust Fabricant

NPA reaches a settlement to its complaint alleging current and former board members plotted to oust CEO Daniel Fabricant. The trade group remains embroiled in a wrongful dismissal complaint filed by former CFO Brent Weickert.

NPA's Former CFO Alleges Improper Expenses By Fabricant, Religious And Gender Harassment

CEO Daniel Fabricant and the NPA board's president say former CFO Brent Weickert's allegations in a complaint filed in California state court are baseless. Weickert, with NPA from 1997 until October, says he was dismissed after he stated his concerns to NPA's board and to Fabricant.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel